Humoral Response in Hemodialysis Patients Following COVID-19 Vaccination and Breakthrough Infections during Delta and Omicron Variant Predominance

被引:12
|
作者
Chinnadurai, Rajkumar [1 ,2 ]
Wu, Henry H. L. [2 ,3 ]
Cox, Eleanor [1 ]
Moore, Jayne [1 ]
Clough, Toni [1 ]
Lamerton, Elizabeth [1 ]
Donne, Rosie [1 ]
O'Riordan, Edmond [1 ]
Poulikakos, Dimitrios [1 ,2 ]
机构
[1] Northern Care Alliance NHS Fdn Trust, Dept Renal Med, Salford M6 8HD, Lancs, England
[2] Univ Manchester, Fac Biol Med & Hlth, Manchester M13 9PL, Lancs, England
[3] Lancashire Teaching Hosp NHS Fdn Trust, Dept Renal Med, Preston PR2 9HT, Lancs, England
关键词
COVID-19; vaccination; humoral response; hemodialysis; breakthrough infections; Delta variant; Omicron variant; HEPATITIS-B VACCINE; ANTIBODY-RESPONSE;
D O I
10.3390/vaccines10040498
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The advancement of COVID-19 vaccination programs globally has been viewed as an integral strategy to reduce both the number of COVID-19 cases and consequential complications of COVID-19, particularly for high-risk patient groups. There are limited data on the antibody response and protection from disease infection and severity in patients requiring hemodialysis (HD) following COVID-19 vaccination during the Delta and Omicron variant predominance. We conducted a study aiming to evaluate humoral immunity derived from two different COVID-19 vaccines administered to our in-centre HD population and investigated the characteristics of breakthrough COVID-19 infections occurring post-vaccination within this population. Methods: This is a prospective observational study including patients receiving HD at Salford Royal Hospital. The first and second doses of COVID-19 vaccinations (Pfizer BioNTech BNT162b2 or Oxford AstraZeneca ChAdOx1 nCoV-19) were administered to this patient cohort since January 2021. The incidence of any breakthrough COVID-19 infections occurring in double vaccinated patients between 1 April 2021 and 15 January 2022 was recorded. Patients were screened weekly with nasal and pharyngeal nasopharyngeal swabs for real-time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) for COVID-19, whilst SARS-CoV-2 antibody testing was performed alongside monthly routine HD bloods. Results: Four hundred eleven patients receiving HD were included in this study, of which 170 of 178 patients (95.5%) with available data on antibody status following two doses of the Pfizer BioNTech BNT162b2 vaccination had detectable antibody response, whilst this was the case for 97 of 101 patients (96.1%) who received two doses of the Oxford AstraZeneca ChAdOx1 nCoV-19 vaccine. For 12 seronegative patients who received a booster vaccine (third dose), nine seroconverted, while one remained negative and two were not tested. No statistically significant differences were observed with regards to antibody status between those receiving Pfizer BioNTech BNT162b2 and Oxford AstraZeneca ChAdOx1 nCoV-19 vaccines. Sixty-three of 353 patients with two doses of COVID-19 vaccination had breakthrough COVID-19 infection (40 during Delta and 23 during Omicron variant predominance). Of the 40 patients during the delta period, five were admitted into hospital and there were two reported deaths due to COVID-19-related illness. There were no COVID-19 associated hospitalizations or deaths during the Omicron variant predominance. Conclusions: The vast majority of HD patients who received two doses of the Pfizer BioNTech BNT162b2 or Oxford AstraZeneca ChAdOx1 nCoV-19 vaccinations developed detectable antibody responses. Our results support the value of booster vaccination with mRNA-based COVID-19 vaccine in HD patients and highlight the need for ongoing surveillance programmes with rRT-PCR and antibody testing for timely detection of positive cases.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Breakthrough SARS-CoV-2 infections during periods of delta and omicron predominance, South Africa
    Goga, Ameena
    Bekker, Linda-Gail
    Garrett, Nigel
    Reddy, Tarylee
    Yende-Zuma, Nonhlanhla
    Fairall, Lara
    Moultrie, Harry
    Takalani, Azwidihwi
    Trivella, Valentina
    Faesen, Mark
    Bailey, Veronique
    Seocharan, Ishen
    Gray, Glenda E.
    [J]. LANCET, 2022, 400 (10348): : 269 - 271
  • [32] Breakthrough COVID-19 Infection During the Delta Variant Dominant Period: Individualized Care Based on Vaccination Status Is Needed
    Lee, Chan Mi
    Lee, Eunyoung
    Park, Wan Beom
    Choe, Pyoeng Gyun
    Song, Kyoung-Ho
    Kim, Eu Suk
    Park, Sang-Won
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, 37 (32)
  • [33] COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge
    Bronstein, Yotam
    Gat, Roi
    Levi, Shai
    Cohen, Yael C.
    Luttwak, Efrat
    Benyamini, Noam
    Shragai, Tamir
    Vitkon, Roy
    Neaman, Miriam
    Eilaty, Nili
    Levi, Mor
    Trestman, Svetlana
    Perry, Chava
    Herishanu, Yair
    Avivi, Irit
    [J]. CANCER CELL, 2022, 40 (06) : 578 - 580
  • [34] Antibody response to COVID-19 vaccination in patients on chronic hemodialysis
    Choi, Heejung
    Han, Sungdam
    Kim, Ji Su
    Park, Bumhee
    Lee, Min-Jeong
    Shin, Gyu-Tae
    Kim, Heungsoo
    Kim, Kyongmin
    Park, A. -Young
    Shin, Ho-Joon
    Park, Inwhee
    [J]. CLINICAL AND EXPERIMENTAL VACCINE RESEARCH, 2023, 12 (03) : 249 - 259
  • [35] Features of the Humoral Response to Infection, Vaccination, and Revaccination during COVID-19
    Kombarova, S. Yu
    Aleshkin, A., V
    Novikova, L., I
    Bochkareva, S. S.
    Zatevalov, A. M.
    Mekhtiev, E. R.
    Mizaeva, T. E.
    Basov, A. A.
    Borisova, O. Yu
    Likhanskaya, E., I
    Voropaeva, E. A.
    Urban, Yu N.
    Mitrokhin, S. D.
    Shkoda, A. S.
    Gushchin, V. A.
    Sinyavin, A. E.
    Nikiforova, M. A.
    Lebedin, Yu S.
    Karaulov, A., V
    [J]. BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2022, 173 (06) : 734 - 739
  • [36] Features of the Humoral Response to Infection, Vaccination, and Revaccination during COVID-19
    S. Yu. Kombarova
    A. V. Aleshkin
    L. I. Novikova
    S. S. Bochkareva
    A. M. Zatevalov
    E. R. Mekhtiev
    T. E. Mizaeva
    A. A. Basov
    O. Yu. Borisova
    E. I. Likhanskaya
    E. A. Voropaeva
    Yu. N. Urban
    S. D. Mitrokhin
    A. S. Shkoda
    V. A. Gushchin
    A. E. Sinyavin
    M. A. Nikiforova
    Yu. S. Lebedin
    A. V. Karaulov
    [J]. Bulletin of Experimental Biology and Medicine, 2022, 173 : 734 - 739
  • [37] Laryngo pharyngeal affection of COVID-19 during Delta and Omicron variant (Comparative Study)
    Anwar, Hanan
    Ragab, Ahmed
    Rashad, Asmaa El-Dessouky
    [J]. EGYPTIAN JOURNAL OF OTOLARYNGOLOGY, 2024, 40 (01):
  • [38] The impact of vaccination on patients with COVID-19 during the wave of Omicron in Shanghai
    Yu, Chen
    Zhu, Fengzhao
    Wu, Hongmei
    Lei, Zeyuan
    Yu, Liu
    Guo, Yuhang
    Shen, Rufei
    Jia, Qingzhu
    Sun, Xiaorong
    Xia, Wang
    Song, Caiping
    Zhi, Xu
    Luo, Chunmei
    [J]. FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [39] Humoral response to viral vector COVID-19 vaccine in hemodialysis patients
    Raja, Niranjan
    Rajagopalan, Arul
    Arunachalam, Jegan
    Prasath, Arun
    Durai, Rakesh
    Rajendran, Manorajan
    [J]. KIDNEY RESEARCH AND CLINICAL PRACTICE, 2022, 41 (03) : 342 - 350
  • [40] Onodera's prognostic nutritional index: Comparison of its role in the severity and outcomes of patients with COVID-19 during the periods of alpha, delta and omicron variant predominance
    Mathioudakis, Nikolaos
    Zachiotis, Marinos
    Papadakos, Stavros
    Triantafyllou, Maria
    Karapanou, Amalia
    Samara, Stamatia
    Karamanakos, Georgios
    Spandidos, Demetrios A.
    Papalexis, Petros
    Damaskos, Christos
    Tarantinos, Kyriakos
    Fotakopoulos, George
    Sklapani, Pagona
    Trakas, Nikolaos
    Sipsas, Nikolaos V.
    Georgakopoulou, Vasiliki Epameinondas
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 24 (05)